AnaptysBio to Present at the Cantor Fitzgerald Global Healthcare Conference
September 27 2019 - 6:30AM
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology
company developing first-in-class antibody product candidates
focused on unmet medical needs in inflammation, today announced
that Hamza Suria, chief executive officer of AnaptysBio, will
present at the Cantor Fitzgerald Global 2019 Healthcare Conference
on Wednesday, Oct. 2, 2019 at 5:20 p.m. ET in New York City.
A webcast of the presentation will be available through the
investor section of the AnaptysBio website. A replay of the webcast
will be available for 90 days following the event.
About AnaptysBioAnaptysBio is a clinical-stage
biotechnology company developing first-in-class antibody product
candidates focused on unmet medical needs in inflammation. The
Company’s proprietary anti-inflammatory pipeline includes its
anti-IL-33 antibody etokimab, previously referred to as ANB020, for
the treatment of moderate-to-severe atopic dermatitis, eosinophilic
asthma, and adult chronic rhinosinusitis with nasal polyps, or
CRSwNP; its anti-IL-36R antibody ANB019 for the treatment of rare
inflammatory diseases, including generalized pustular psoriasis, or
GPP, and palmoplantar pustulosis, or PPP; and its PD-1 agonist
program, ANB030, and other novel anti-inflammatory checkpoint
receptor modulator antibodies for treatment of certain autoimmune
diseases where immune checkpoint receptors are insufficiently
activated. AnaptysBio’s antibody pipeline has been developed using
its proprietary somatic hypermutation, or SHM platform, which uses
in vitro SHM for antibody discovery and is designed to replicate
key features of the human immune system to overcome the limitations
of competing antibody discovery technologies. AnaptysBio has also
developed multiple therapeutic antibodies in an immuno-oncology
partnership with TESARO, a GSK company, including an anti-PD-1
antagonist antibody (dostarlimab (TSR-042)), which is anticipated
to achieve BLA filing in late 2019, an anti-TIM-3 antagonist
antibody (TSR-022) and an anti-LAG-3 antagonist antibody (TSR-033),
and an inflammation partnership with Celgene, including an
anti-PD-1 checkpoint agonist antibody (CC-90006) currently in
clinical development.
Contact:Eric Loumeau
AnapytsBio, Inc.858.362.6348eloumeau@anaptysbio.com
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Aug 2024 to Sep 2024
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Sep 2023 to Sep 2024